Pasar al contenido principal

EXPLORANDO LAS ALTERACIONES DEL ADN MITOCONDRIAL COMO DIANA TERAPEUTICA EN LA ENFERMEDAD DE ALZHEIMER

PID2022-143279OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Induction of the inflammasome pathway by tyrosine kinase inhibitors provides an actionable therapeutic target for hepatocellular carcinoma

  • Tutusaus, Anna
  • Sanduzzi Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell, Anna
  • Marí, Montserrat
  • Reig, María
  • Morales, Albert
During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma

  • Tutusaus, Anna
  • Sanduzzi-Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell Riera, Anna
  • Marí, Montserrat
  • Reig, Maria
  • Morales, Albert
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Simple Summary: In the past decade, tyrosine kinase inhibitors sorafenib and regorafenib have been standard treatments for advanced liver cancer. Previous studies have associated sorafenib with inflammasome activation, but its therapeutic role in patients has not been explored. Our study found that both treatments altered inflammasome-related gene expression, showing a similar transcriptomic pattern in a mouse model of liver cancer. In accordance with public databases, inflammasome genes are associated with a poorer prognosis in male liver cancer patients, without changes in females. Thus, we analyzed biopsies from hepatocellular carcinoma patients treated with sorafenib/regorafenib and confirmed inflammasome activation. In experimental models, inflammasome inhibition enhanced sorafenib effectiveness, demonstrating its potential to overcome therapy resistance and improve its efficacy for liver cancer treatment., Abstract: During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder

  • Puigros Serra, Margalida
  • Ivars, Elia
  • Calderón, Anna
  • Martín-Ruiz, Daniel
  • Serradell, Mònica
  • Fernández Ortiga, Manel
  • Muñoz-Lopetegi, Amaia
  • Mayà, Gerard
  • Santamaria, Joan
  • Gaig, Carles
  • Colell Riera, Anna
  • Tolosa, Eduardo;
  • Iranzo, Alex
  • Trullas, Ramón
Trabajo presentado en la International Conference on Neurodegenerative Disorders, celebrada en Lisboa (Portugal), del 19 al 21 de septiembre de 2024, Background: Idiopathic REM sleep behaviour disorder (IRBD) represents the prodromal stage of Lewy body disorders (Parkinson¿s disease (PD) and dementia with Lewy bodies (DLB)) which are linked to variations in circulating cell-free mitochondrial DNA (cf-mtDNA). Here, we assessed whether altered cf-mtDNA release and integrity are already present in IRBD. Methods: We used multiplex digital PCR to quantify cf-mtDNA copies and deletion ratio in CSF and serum in a cohort of 71 subjects, including 1) 17 patients with IRBD who remained disease-free (non-converters), 2) 34 patients initially diagnosed with IRBD who developed either PD or DLB (converters), and 3) 20 age-matched controls without IRBD or Parkinsonism. In addition, we investigated whether CD9-positive extracellular vesicles (CD9-EVs) from CSF and serum samples contained cf-mtDNA. Findings: Patients with IRBD, both converters and non-converters, exhibited more cf-mtDNA with deletions in the CSF than controls. This finding was confirmed in CD9-EVs. The high levels of deleted cf-mtDNA in CSF corresponded to a significant decrease in cf-mtDNA copies in CD9-EVs in both IRBD non-converters and converters. Conversely, a significant increase in cf-mtDNA copies was found in serum and CD9-EVs from the serum of patients with IRBD who later converted to a Lewy body disorder. Interpretation: Alterations in cf-mtDNA copy number and deletion ratio known to occur in Lewy body disorders are already present in IRBD and are not a consequence of Lewy body disease conversion., suggesting that mtDNA dysfunction is a primary molecular mechanism of the pathophysiological cascade that precedes the full clinical motor and cognitive manifestation of Lewy body disorders., Funded by Michael J. Fox Foundation research grant MJFF-001111. Funded by MICIU/AEI/10.13039/501100011033 “ERDF A way of making Europe”, grants PID2020-115091RB-I00 (RT) and PID2022-143279OB-I00 (ACo). Funded by Instituto de Salud Carlos III “European Union NextGenerationEU/PRTR”, grant PMP22/00100 (RT and ACo). Funded by AGAUR/Generalitat de Catalunya, grant SGR00490 (RT and ACo). MP has an FPI fellowship, PRE2018-083297, funded by MICIU/AEI/10.13039/501100011033 “ESF Investing in your future”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroinflammation in Age-Related Neurodegenerative Diseases: Role of Mitochondrial Oxidative Stress

  • Abadin, Xenia
  • Dios, Cristina de
  • Zubillaga, Marlene
  • Ivars, Elia
  • Puigros Serra, Margalida
  • Marí, Montserrat
  • Morales, Albert
  • Vizuete, Marisa
  • Vitorica, Javier
  • Trullas, Ramón
  • Colell Riera, Anna
  • Roca-Agujetas, Vicente
A shared hallmark of age-related neurodegenerative diseases is the chronic activation of innate immune cells, which actively contributes to the neurodegenerative process. In Alzheimer's disease, this inflammatory milieu exacerbates both amyloid and tau pathology. A similar abnormal inflammatory response has been reported in Parkinson's disease, with elevated levels of cytokines and other inflammatory intermediates derived from activated glial cells, which promote the progressive loss of nigral dopaminergic neurons. Understanding the causes that support this aberrant inflammatory response has become a topic of growing interest and research in neurodegeneration, with high translational potential. It has been postulated that the phenotypic shift of immune cells towards a proinflammatory state combined with the presence of immunogenic cell death fuels a vicious cycle in which mitochondrial dysfunction plays a central role. Mitochondria and mitochondria-generated reactive oxygen species are downstream effectors of different inflammatory signaling pathways, including inflammasomes. Dysfunctional mitochondria are also recognized as important producers of damage-associated molecular patterns, which can amplify the immune response. Here, we review the major findings highlighting the role of mitochondria as a checkpoint of neuroinflammation and immunogenic cell deaths in neurodegenerative diseases. The knowledge of these processes may help to find new druggable targets to modulate the inflammatory response., This research was funded by MCIN/AEI/10.13039/501100011033, co-funded by NextGenera-tionEU/PRTR, and by “ERDF A way of making Europe”, grants PID2022-143279OB-100 (A.C.), PID2021-123564OB-100 (A.M.), PDC2023-145806-100 (A.M and M.M.), PID2020-115091RB-I00 (R.T.), and RED2022-134786-T (A.C. and R.T.); Instituto de Salud Carlos III (ISCIII) and European Union NextGenerationEU/PRTR, grants PMP22/00100 (R.T. and A.C.) and PI22/00475 (M.M.); Fundació la Marató de TV3 (A.M.); AGAUR, grant 2021-SGR00490 (A.C.); and Junta de Andalucia (Consejería de Economia y Conocimiento) co-funded by FEDER 214-2020 and by the CIBERNED (Convocatoria 2022 Proyectos Colaborativos 2020/21), grants US-1262734 (J.V.) and P20-00843 (J.V.). V.R.-A. has a Juan de la Cierva postdoctoral contract (JDC2022-048952-I) funded by MCIN/AEI/10.13039/501100011033 and by NextGenerationEU/PRTR. C.D. has a contract (2022 INV-1 00065) funded by “Programa Investigo” MCIN/PRTR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Copper overload worsens the inflammatory response of microglia to amyloid beta (Aβ) by impairing phagocytosis and promoting mitochondrial DNA-mediated NLRP3 inflammasome activation

  • Zubillaga, Marlene
  • Abadin, Xenia
  • Ivars, Elia
  • Puigros Serra, Margalida
  • Trullas, Ramón
  • Bellini, María José
  • Arnal, Nathalie
  • Colell Riera, Anna
Microglia play a significant role in the development and progression of Alzheimer's disease (AD). These brain-resident immune cells efficiently clear neurotoxic amyloid beta (Aβ) peptides; however, chronic activation may overwhelm their protective abilities, resulting in persistent neuroinflammation. The causes of aberrant microglial activation in AD remain elusive. Emerging evidence indicates that copper (Cu) accumulation, which can arise from prolonged exposure to various environmental sources, modifies the innate immune response in AD. Here, we sought to explore the mechanisms by which Cu overload regulates the microglial phenotype when exposed to Aβ. Our findings showed that exposure to sublethal doses of Cu led to the accumulation of this transition metal in the mitochondria. Elevated mitochondrial Cu (mtCu) levels were accompanied by reduced mitochondrial glutathione (mtGSH) and high oxidative stress, leading to Aβ-induced inflammasome activation through the release of oxidized mitochondrial DNA (ox-mtDNA). Moreover, increased intracellular Cu levels enhanced cholesterol biosynthesis and facilitated its transport to mitochondria. The combination of elevated cholesterol and mitochondrial oxidative stress hindered the ability of microglia to phagocytose Aβ effectively. As expected, conditioned medium from Cu-activated microglia reduced neuronal viability. The neurotoxicity caused by Cu-overloaded microglia was prevented by inhibiting inflammasome activation and restoring mtGSH levels. In conclusion, our study outlines a mechanistic pathway by which chronic exposure to environmental Cu may lead to neuroinflammation and Aβ accumulation in AD, underscoring the crucial role of mitochondrial oxidative stress., This work was funded by the MCIN/AEI/10.13039/501100011033, co-funded by NextGenerationEU/PRTR, and by “ERDF A way of making Europe”, grants PID2022-143279OB-100 (A.C.), PID2023-153168OB-100 (R.T.) and RED2024-154130-T (A.C. and R.T.); by the Instituto de Salud Carlos III (ISCIII) and European Union NextGenerationEU/PRTR, grants PMP22/00100 (R T. and A.C.); by the CSIC, grant COOPA20476 (A C. and N.A.), by the AGAUR, Generalitat de Catalunya, grant 2021-SGR00490 (A.C.), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma

  • Rider, Patricia
  • Tutusaus, Anna
  • Cuño-Gómiz, Carlos
  • Savino, Flavia
  • Marsal, Aida
  • Llarch, Neus
  • Iserte, Gemma
  • Colell, Anna
  • García de Frutos, Pablo
  • Hernáez-Alsina, Tania
  • Sanduzzi-Zamparelli, Marco
  • Marí, Montserrat
  • Reig, María
  • Morales, Albert
BACKGROUND: Cabozantinib, a tyrosine kinase inhibitor (TKI) approved for advanced hepatocellular carcinoma (HCC), has established clinical benefit although the underlying immunomodulatory mechanisms, particularly those involving mitochondrial stress and the cGAS/STING pathway, remain poorly defined. METHODS: We assessed cabozantinib’s effects on mitochondrial integrity and innate immune signaling in hepatoma cells and macrophage cell lines, analyzing mitochondrial depolarization, reactive oxygen species production, cytosolic release of mitochondrial DNA (mtDNA), activation of the cGAS/STING pathway and induction of type I interferon-stimulated genes (ISGs). Functional relevance was tested by mtDNA depletion and CRISPR-mediated STING knockdown. The in vivo effects of cabozantinib and the STING agonist DMXAA were examined in immunocompetent mouse models. Translational relevance was evaluated by multiplex proteomic profiling of serum samples from 18 cabozantinib-treated HCC patients across two independent cohorts. RESULTS: Cabozantinib induced mitochondrial depolarization, oxidative stress, and cytosolic mtDNA release, resulting in STING-dependent signaling and ISG upregulation in hepatoma cells. Disruption of mtDNA or STING abrogated these effects. In vivo, cabozantinib reduced tumor growth and promoted tumor-infiltrating lymphocyte activation, which were further enhanced by DMXAA co-treatment. Patient serum proteomics revealed consistent increases in immune and stress-related proteins (e.g., granzyme B, HO-1, CAIX, CXCL13) and decreases in angiogenic and immunosuppressive factors (e.g., VEGFR-2, ANGPT1/2, CCL17), paralleling the systemic immune remodeling observed in preclinical models. Both baseline immune signatures and treatment-induced protein shifts were associated with clinical outcome. CONCLUSIONS: Cabozantinib promotes tumor immunogenicity through mitochondrial disruption and cGAS/STING activation, leading to immune remodeling in HCC. These findings provide mechanistic insight into the immunomodulatory effects of cabozantinib, support rational combinations with STING agonists, and highlight candidate biomarkers for predicting therapeutic response in TKI-treated patients., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Projects# PID2022-143279OB-100 to AC, PID2021–123564OB-I00 and PDC2023-145806-100 to AM and PG funded by MCIN/AEI/10.13039/501100011033 and co-funded by “ERDF A way of making Europe” and PERTE-CHIP program. Project# PI22/00475 and PI25/00398 to MM and PI22/01427 to MR funded by Instituto de Salud Carlos III and co-funded by the European Union “ERDF A way of making Europe”; AGAUR (2021_SGR_490) and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Picrosirius red, polarized light microscopy, and curvelet transform analysis: An improved method for liver fibrosis assessment

  • Cuño-Gómiz, Carlos
  • Tutusaus, Anna
  • Savino, Flavia
  • Rider, Patricia
  • Colell, Anna
  • Morales, Albert
  • Marí, Montserrat
Liver fibrosis is a hallmark of chronic liver diseases, characterized by excessive extracellular matrix deposition and structural alterations. Conventional histological assessments rely on qualitative or semi-quantitative scoring systems that may lack sensitivity for subtle fibrotic changes. Here, we present an improved fibrosis evaluation method integrating Picrosirius Red (PSR) staining, polarized light (PL) microscopy, and curvelet transform-based fiber analysis (CT-FIRE). This approach provides a quantitative and reproducible assessment of collagen fiber morphology and composition. Applied to murine models of metabolic dysfunction-associated steatohepatitis (MASH)-induced fibrosis, our method reveals novel insights into fibrosis progression and strain-dependent variations. This enhanced workflow offers a cost-effective, high-resolution tool for fibrosis analysis in preclinical research., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021–123564OB-I00 and PDC2023–145806-I00 to A.M, PID2022–143279OB-100 to A.C., funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Induction of the inflammasome pathway by tyrosine kinase inhibitors provides an actionable therapeutic target for hepatocellular carcinoma

  • Tutusaus, Anna
  • Sanduzzi Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell, Anna
  • Marí, Montserrat
  • Reig, María
  • Morales, Albert
During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya.